Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Claire Vennin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9088-4177; OpenAlex author ID A5016753421. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 4 papers · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 19

  1. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  2. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  3. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  4. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  5. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  6. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  7. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  8. Targeting genetically-tuned CAFs in pancreatic cancer via perlecan manipulation. Co-author DOI 10.1080/14728222.2020.1727887↗
  9. Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy. Co-author DOI 10.1080/21541248.2017.1345712↗
  10. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. First author DOI 10.1016/j.trecan.2019.09.010↗
  11. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  12. Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2018.05.038↗
  13. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2017.11.280↗
  14. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2017-315144↗
  15. Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth. Co-author DOI 10.1158/0008-5472.can-17-1339↗
  16. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Co-author DOI 10.1038/onc.2017.63↗
  17. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Co-author DOI 10.1126/scitranslmed.aai8504↗
  18. Transient targeting of the pancreatic cancer stroma as a 'fine-tuned' anti-tumor and anti-metastatic therapy. Co-author DOI 10.18632/oncotarget.21468↗
  19. Imaging fibrosis in pancreatic cancer using second harmonic generation. Co-author DOI 10.1016/j.pan.2015.02.004↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paul Timpson · 11 shared papers, 2015–2021 · strength 1.00
  2. Marina Pajic · 9 shared papers, 2015–2021 · strength 0.74
  3. Jennifer P. Morton · 6 shared papers, 2017–2021 · strength 0.44
  4. Thomas R. Cox · 5 shared papers, 2017–2021 · strength 0.43
  5. Brooke Pereira · 3 shared papers, 2019–2021 · strength 0.34
  6. David Herrmann · 4 shared papers, 2017–2021 · strength 0.29
  7. Kendelle Joan Murphy · 4 shared papers, 2018–2021 · strength 0.29
  8. Shona Ritchie · 2 shared papers, 2020–2021 · strength 0.24
  9. Nicola Rath · 2 shared papers, 2018–2020 · strength 0.21
  10. Michael F. Olson · 2 shared papers, 2018–2020 · strength 0.21
  11. James R. W. Conway · 3 shared papers, 2017–2021 · strength 0.19
  12. Owen James Sansom · 3 shared papers, 2018–2021 · strength 0.19
  13. Andrew Victor Biankin · 3 shared papers, 2017–2021 · strength 0.19
  14. Cecilia R. Chambers · 2 shared papers, 2019–2021 · strength 0.18
  15. Yingxiao Wang · 2 shared papers, 2018–2021 · strength 0.14
  16. Max Nobis · 2 shared papers, 2018–2021 · strength 0.14
  17. Ashleigh Parkin · 2 shared papers, 2018–2021 · strength 0.13
  18. Jaswinder Singh Samra · 2 shared papers, 2018–2021 · strength 0.13
  19. Angela S. Y. Chou · 2 shared papers, 2018–2021 · strength 0.13
  20. Amber L. Johns · 2 shared papers, 2018–2021 · strength 0.13
  21. Sean Michael Grimmond · 2 shared papers, 2018–2021 · strength 0.13
  22. Anthony James Gill · 2 shared papers, 2018–2021 · strength 0.13
  23. Mark J. Cowley · 2 shared papers, 2017–2018 · strength 0.11
  24. Michael Tayao · 1 shared paper, 2021 · strength 0.08
  25. Roger J. Daly · 1 shared paper, 2021 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.